B
14.48
0.58 (4.17%)
| Penutupan Terdahulu | 13.90 |
| Jumlah Dagangan | 2,921,344 |
| Harga / Buku (P/B) | 191.77 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -9.25 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.68% |
| Nisbah Semasa (MRQ) | 2.33 |
| Aliran Tunai Operasi (OCF TTM) | -644.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -394.10 M |
| Pulangan Atas Aset (ROA TTM) | -129.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -316.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Biohaven Ltd. | Bercampur | Menurun |
AISkor Stockmoo
| Nilai 35% | -0.2 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -0.2 |
| Masa 35% | 2.8 |
| AI Technical info | NA |
| Osilator Teknikal info | 4.0 |
| Purata Bergerak Teknikal info | 1.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×0.79 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.4% |
| Persetujuan Tonggak | ×1.18 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | -0.9 |
| Skor Akhir | 0.85 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 11.96% |
| % Dimiliki oleh Institusi | 90.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Montanova Capital, Llc | 30 Jun 2026 | 10,286,937 |
| Infinitum Asset Management, Llc | 30 Jun 2026 | 6,250,000 |
| Royalty Pharma Sub-Manager, Llc | 30 Jun 2026 | 2,936,507 |
| Cormorant Asset Management, Lp | 30 Jun 2026 | 2,610,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |